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Background/aim: Extended spectrum beta lactamase (ESBL) production among E. coli is one of the principal mechanisms that augment
resistance to antibiotics. In the current study the molecular detection of class A beta lactamases among uropathogenic Escherichia coli
was evaluated.
Materials and methods: A total of 355 urine samples were collected from a tertiary care hospital in Peshawar. The ESBL production
among E. coli isolates was detected by using the disc synergy diffusion method. Moreover, the molecular detection of bla TEM-1 and bla
CTX-M-1 ESBLs, the antibiotic resistance pattern, and the minimum inhibitory concentrations (MICs) were also documented.
Results: Among the 355 urine samples, 157 isolates were E. coli, and 23.56% of the isolates were ESBL E. coli. Among phenotypic ESBL
producers, bla CTX-M-1 and bla TEM-1 were found in 59.45% and 40.54% of the isolates, respectively. A high resistance rate was
observed against aztreonam (97.29%), while the lowest resistance was observed against imipenem (2.7%). The MICs of ESBLs E. coli for
ceftriaxone, ciprofloxacin, and gentamicin was >512 µg/mL, 4 µg/mL to 128 µg/mL, and 1 µg/mL to 14 µg/mL respectively.
Conclusion: The present study showed that bla CTX-M-1 ESBL production is more prevalent in our clinical E. coli isolates. More often
the ESBLs were resistant to commonly used antibiotics.
Key words: Urinary tract infection, E. coli, ESBLS, bla CTX-M-1, bla TEM-1, antibiotics profile

1. Introduction
Urinary tract infection (UTI) is the invasion and
inflammation of the urinary tract structures caused by
microbial agents in human (1,2). About 150 million people
worldwide are diagnosed with UTI each year (3). Bacterial
agents like Enterobacteriaceae are frequently isolated from
UTI samples (84.3%) (4). Among Enterobacteriaceae,
Escherichia coli is the most common causative agent of
UTI (5).
UTIs are mainly treated with beta lactam antibiotics;
however, acquired resistance to these antibiotics in UTI
pathogens is commonly augmented by bacterial enzymes,
and leads to the emergence of extended spectrum beta
lactamases (ESBLs) (6). ESBL producing pathogens of bla
TEM and bla SHV types were primarily hospital acquired
and were usually produced by several enteric bacterial
pathogens; however, this scenario has been changed
* Correspondence: hazirrahman@hotmail.com

(6,7). Among bla TEM, type TEM-1 was early described
and is able to hydrolyze penicillin and early generation
cephalosporins (7).
CTX-M ESBLs are another type of beta lactamases that
have been widely reported in E. coli (6–8). CTX-M-1 type
beta lactamases confer resistance to expanded-spectrum
cephalosporins (8). As far as literature mining is concerned,
we have not found any study about the occurrence of bla
CTX-M-1 and bla TEM-1 among uropathogenic E. coli in
Pakistan.
The present study documented the molecular
prevalence of bla CTX-M-1 and bla TEM-1 ESBL producing
E. coli causing urinary tract infections. Furthermore, the
isolates were tested for antibiotic resistance pattern against
commonly used antibiotics. The findings of the current
study will be helpful for the control of antibiotic resistance
among E. coli isolates from UTI patients.
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2. Materials and methods
2.1. Samples
This study was conducted at the Department of
Microbiology, Kohat University of Science and Technology,
Kohat, Pakistan, from April 2013 to January 2014. A total
of 355 urine samples were collected from suspected UTI
patients at a tertiary care hospital in Peshawar. Written
consent was taken from each patient included in the study.
The departmental ethical review board approved the study.
2.2. Processing of samples
All urine samples were inoculated on cystine lactose
electrolyte deficient (CLED) agar (Oxoid, UK). These
plates were incubated overnight at 37 °C aerobically. Only
those samples were processed for ESBL production that
showed significant growth and were identified as E. coli on
the basis of culture and biochemical characteristics.
2.3. Determination of ESBL E. coli
ESBL production of E. coli isolates was investigated as
described by Jarlier et al. (9). Briefly, 0.5 McFarland dilution
of the test isolate in nutrient broth was swabbed on Mueller
Hinton agar (MHA). An amoxicillin/clavulanic acid
(AMC, 20/10 µg) disc was placed at the center of the MHA
plate while discs of aztreonam (ATM, 30 µg), ceftazidime
(CAZ, 30 μg), cefotaxime (CTX, 30 μg), and ceftriaxone
(CRO, 30 μg) were placed in close proximity of 15 mm
distance. The inhibition zone of cephalosporin towards
the AMC disc was interpreted as an ESBL producer. E. coli
ATCC 25922 strain was used as quality control with disc
diffusion and tube dilution assays.
2.4. Molecular detection of bla (CTX-M-1) bla (TEM-1)
ESBLs
Polymerase chain reaction (PCR) was employed to detect
genes responsible for the ESBL producers. DNA amplification
of the blaCTX-M-1 coding region (780 bp) was performed
using forward (5’-CGTCACGCTGTTGTTAGGAA-3’)
and reverse (5’-ACGGCTTTCTGCCTTAGGTT-3’)
primers, while a 966 bp fragment corresponding to the
blaTEM-1 entire coding region was amplified by using a
forward (5’-TCGGGGAAATGTGCG-3’) and a reverse
primer (5’-TGCTTAATCAGTGAGGCACC-3’) (10).
Briefly, DNA was extracted by NucleoSpin tissue kit
(Macherey-Nagel, Germany). For PCR amplification, 1
µL of template DNA was added to 25 µL of the master
mixture having 1.5 µL of DNTP mixture (0.2 mM of
each), 2.5 µL of PCR buffer , 0.5 µL of Taq polymerase,
0.5 µL of each primer stock solution (50 pmol/µL), and 0.5
µL of MgCl2, and the remaining 18 µL volume was filled
by nuclease free water (Fermentas, USA). The amplified
product was resolved on agarose gel and visualized under
a UV transilluminator.
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2.5. Antibiotics susceptibility patterns of ESBLs E. coli
The antibiotic sensitivity pattern of ESBL E. coli isolates
was determined by the standard Kirby–Bauer method (11).
Briefly, a 0.5 McFarland dilution of the already refreshed
bacterial isolate in nutrient broth was swabbed on MHA.
Antibiotic discs (Oxoid, UK) of known concentration were
placed on the MHA plates and then incubated overnight
at 35 ± 2 °C. Following incubation, the zone of inhibition
was measured and interpreted as discussed in the Clinical
Laboratory Standard Institute (CLSI) guidelines (12).
Susceptibility (minimum inhibitory concentration (MIC))
to colistin sulfate (CT-10 µg) and tigecycline (TGC-15 µg)
was measured by the broth dilution method.
2.6. Determination of MICs
MICs were determined using the standard two-fold
tube dilution method for ceftriaxone, ciprofloxacin, and
gentamicin (13).
3. Results
Approximately one-third of the 157 E. coli isolates
showed ESBL activity as shown in Figure 1. Thus, the
overall prevalence was 23.56% (n = 37), while non-ESBL
producers were 76.43% (n = 120).
ESBL E. coli isolates (n = 37) were subjected to PCR
to identify the presence of bla CTX-M-1 and bla TEM1 genes. A total of 33 (89.18%) isolates were positive for
bla CTX-M-1 and bla TEM-1 genes. Individually, bla
CTX-M-1 was detected in 22 (59.54%) isolates and bla

Figure 1. Phenotypic detection of ESBL producing E. coli. The
AMC (amoxicillin/clavulanic acid) disc was placed at the center
of the agar plate, while the discs of ATM (aztreonam), CAZ
(ceftazidime), CRO (ceftriaxone), and CTX (cefotaxime) were
placed in close proximity. The resistance of the E. coli isolate to
all cephalosporin and aztreonam, and the synergy between AMC
and CAZ, phenotypically confirmed the ESBL production.
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TEM-1 was detected in 15 (40.54%) isolates of ESBL E.
coli. The size of the amplified bla CTX-M-1 and bla TEM1 genes was 780 bp and 971 bp, respectively (Figure 2).
Moreover, the antibiotic susceptibility pattern of ESBL
E. coli was determined. ESBL producing E. coli were
resistant to aztreonam (n = 36; 97.29%) and ceftriaxone
(n = 35; 94.59%). Nineteen (51%) ESBL producing E.
coli were susceptible to piperacillin/tazobactam, while 18
(49%) were susceptible to fosfomycin (FOS50); however,
imipenem showed excellent activity (n = 35; 94.59%)
against ESBL producing E. coli (Table).

MICs were determined for selected drugs commonly
used against ESBL E. coli. It was found that the MIC of
ceftriaxone was >512 µg/mL against ESBL E. coli isolates,
followed by ciprofloxacin, which ranged from 4 µg/mL to
128 µg/mL, and gentamicin, which ranged from 1 µg/mL
to 14 µg/mL.
4. Discussion
UTIs are caused by a microbial attack and succeeding
multiplication in the urinary tract (14). It is the most
common form of infection, mainly caused by E. coli. In the

Figure 2. Molecular detection of bla CTX-M-1 and bla TEM-1 ESBLs producing E. coli. (A) bla CTX-M-1 gene amplification. Product
size: 780 bp. L: Ladder (100 bp). 1–3: samples. c+: positive control (Pseudomonas aeruginosa having CTX-M-1); c–: negative control
(Bacillus spp. lack CTX-M-1). (B) bla TEM-1 gene amplification. Product size: 971bp. L: Ladder (100 bp). 4, 6, 7: samples. c+: positive
control (Pseudomonas aeruginosa having TEM-1); c–: negative control (Bacillus spp. lacking TEM-1).
Table. Antibiotic susceptibility patterna of ESBL producing E. coli isolates.
Antibiotics (Abb.)
Colistin sulfate (CST)

Disc content
(µg)

Susceptible
isolates n (%)

a
Intermediate
isolates n (%)

a
Resistant
isolates n (%)

5 (0)

0 (0)

32 (86.48)

Aztreonam (ATM)

10
30

0 (0)

I (2.70)

36 (97.29)

Ceftriaxone (CRO)

30

0 (0)

2 (5.40)

35 (94.59)

Sulfamethoxazole/trimethoprim (SXT)

1.25/23.75

4 (10.81)

5 (13.51)

28 (75. 67)

Nitrofurantoin (F)

300

4 (10.81)

2 (5.40)

31 (83.78)

Ciprofloxacin (CIP)

5

6 (16.21)

1 (2.70)

30 (81.08)

c

Tigecycline (TGC)

15

13 (35.13)

8 (21.62)

16 (43.24)

Gentamicin (CN)

10

11 (29.72)

10 (27.02)

16 (43.24)

Fosfomycin (FOS)

200

18 (48.64)

4 (10.81)

15 (40.54)

19 (51.35)

1 (2.70)

17 (45.94)

35 (94.59)

1 (2.70)

1 (2.70)

b

Piperacillin/tazobactam (TZP)
Imipenem (IPM)

100/10
10

Abb.: abbreviation.
a
= as per CLSI guidelines (12).
b
= Susceptibility was measured by the broth dilution method and interpreted as sensitive (S) if MIC ≤ 2 µg/mL), and resistant (R) if
MIC ≥ 4 µg/mL) (32, 33).
c
= Susceptibility was measured by the broth dilution method and interpreted sensitive (S) if MIC ≤ 2 µg/mL), and resistant (R) if MIC
≥ 8 µg/mL) (34).
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present study, among the suspected cases of UTIs, 44.3%
of the positive cultures were E. coli, which is in agreement
with findings reported by a previous study (15).
Complications in UTIs have been amplified because of
the occurrence of ESBL producing E. coli. ESBLs are the
result of the overuse of third generation cephalosporins
and monobactams (16). It is difficult to craft a valid
similarity of the prevalence of ESBLs because of differences
in the study design (17). Several studies from Pakistan in
2005 reported a 40% ESBL production rate, and two other
studies in 2009 reported a 43% and a 58.7% production
rate, respectively (18,19); in 2011 the production rate was
64% (10). In our study ESBL prevalence was 23.56% and
similar results were reported by another study (20). In
Pakistan the prevalence and distribution of ESBLs differ
geographically (21). The inconsistency in the reported
results has increased the need for an improved method
of ESBL detection and its incorporation into routine
laboratory procedures.
From literature mining we have not found any study
about the prevalence of bla CTX-M-1 and bla TEM1 among uropathogenic E. coli in Pakistan. Therefore,
in the current study, we examined the occurrence
and molecular detection of ESBL producing E. coli by
amplifying bla CTX-M-1 and bla TEM-1 genes (7). In
this study bla CTX-M-1 (59.45%) and bla TEM-1 genes
(40.54%) originated from phenotypically confirmed ESBL
producing E. coli isolates. Shafiq et al. (20) in their study in
2014 reported similar to our results. Epidemiological data
reveal that some enzymes are more regularly reported than
others, but the main enzyme type differs by country and
the varied CTX-M types are frequently reported within a
particular country (22).
A wide range of resistance has been reported in Pakistan
among Enterobacteriaceae and other organisms isolated
from urine to commonly used antibiotics like ampicillin,
tetracycline, and cotrimoxazole (14). Nowadays, organisms
with multiple antibiotic resistance genes are becoming more
prevalent (23). In this study aztreonam and amoxicillin/
clavulanic acid were found 90%–100% resistant; this is in

agreement with other studies (18,24,25). Third generation
cephalosporins have been used for gram negative bacterial
treatment (26). In the present study E. coli was found to be
94% resistant to ceftriaxone (24). This high rate of resistance
may be due to the lack of antibiotic policy and the irrational
use of third generation cephalosporins, mainly ceftriaxone,
in the hospital (27). However, in the current study, E. coli was
highly resistant to ciprofloxacin (81%), which is consistent
with the results of previous findings (90.9%) reported from
Bangladesh (28).
Aminoglycosides show good action against gram
negative rods (29). In the present study 43% of the
isolates were resistant to gentamicin, which is similar to
previous studies (24,25). In 2012, gentamicin resistance in
Pakistan and Bangladesh was reported as 60% and 55.5%,
respectively (18,25,28). This peculiarity may be due to the
nonjudicious use of gentamicin in different regions (30).
Carbapenems are drugs of choice for several infections
caused by bacterial pathogens (18). Imipenem showed the
best results and E. coli resistance was only 2.7%, suggesting
that this antibiotic can still be used for UTI treatment (31).
MICs for ceftriaxone, ciprofloxacin, and gentamicin
ranged from 1 to 1024 µg/ mL, 4 to 128 µg/ mL, and 1
to 32 µg/mL, respectively. High MICs for third generation
cephalosporins make them inappropriate for empirical
therapy. The antibiotic resistance in E. coli isolated from
UTIs indicates the need for careful examination and
antibiotic recommendation following culture sensitivity
tests.
In short, the overall prevalence of ESBLs was 23.56%,
while bla CTX-M-1 production was more prevalent in
E. coli. It was found that imipenem exhibited potential
activity against resistant E. coli and may be an appropriate
choice for the treatment of UTI. These findings will be
helpful for prescribing appropriate antibiotics for UTI
patients infected with E. coli.
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